Literature DB >> 10555762

Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas.

I Cruz1, C J Meijer, J M Walboomers, P J Snijders, I Van der Waal.   

Abstract

Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells use the secretory pathway of perforin/granzymes to kill their target cells. In contrast to NK cells, CTL responses are MHC class I restricted. In this study we analysed the relative activation of CTL and NK cells in relation with MHC class I expression on oral squamous cell carcinomas (OSCCs). MHC class I expression was investigated in 47 OSCCs by immunohistochemistry using HCA2, HC10 and beta2-m antibodies. The presence of CTLs, NK cells, and its activation, was investigated in 21 of these OSCCs using respectively, CD8, CD57 and GrB7 antibodies. The Q-Prodit measuring system was used for quantification of cytotoxic cells. All OSCCs showed weak or absent staining of beta2-m on the cell surface. The absence of beta2-m was significantly associated with absent expression of MHC class I heavy chain as detected by HC10 antibody (P = 0.004). In tumour infiltrates CTLs always outnumbered NK cells, as reflected by the ratio CD57/CD8 being always inferior to one (mean: 0.19; SD: 0.15). The proportion of activated cytotoxic cells as detected by granzyme B expression was generally low (mean: 8.6%; SD 8.9). A clear correlation between MHC class I expression and the relative proportion of NK cells/CTLs was not found. This study shows that the majority of OSCCs show weak or absent expression of MHC class I molecules on the cell surface, possibly due to alterations in the normal beta2-m pathway. The low proportion of granzyme B-positive CTLs/NK cells indicates that the secretory pathway of cytotoxicity is poor in these patients. The lack of correlation between MHC class I expression and CTL/NK cell activation as detected by granzyme-B expression suggests that, next to poor antigen presentation, also local factors seem to determine the final outcome of the cytotoxic immune response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10555762      PMCID: PMC2374311          DOI: 10.1038/sj.bjc.6690780

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

Review 1.  Co-stimulation in T cell responses.

Authors:  C A Chambers; J P Allison
Journal:  Curr Opin Immunol       Date:  1997-06       Impact factor: 7.486

Review 2.  IL-2-induced cellular events.

Authors:  J Gómez; A González; C Martínez-A; A Rebollo
Journal:  Crit Rev Immunol       Date:  1998       Impact factor: 2.214

Review 3.  Lymphocyte granule-mediated apoptosis: matters of viral mimicry and deadly proteases.

Authors:  C J Froelich; V M Dixit; X Yang
Journal:  Immunol Today       Date:  1998-01

Review 4.  Killing mechanisms of cytotoxic lymphocytes.

Authors:  G Berke
Journal:  Curr Opin Hematol       Date:  1997-01       Impact factor: 3.284

5.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

Review 6.  Antigen presentation by class I major histocompatibility complex molecules: a context for thinking about HLA-G.

Authors:  P Parham
Journal:  Am J Reprod Immunol       Date:  1995-07       Impact factor: 3.886

7.  Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays.

Authors:  M N Bobrow; T D Harris; K J Shaughnessy; G J Litt
Journal:  J Immunol Methods       Date:  1989-12-20       Impact factor: 2.303

8.  Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer.

Authors:  T L Whiteside; K Chikamatsu; S Nagashima; K Okada
Journal:  Anticancer Res       Date:  1996 Jul-Aug       Impact factor: 2.480

9.  Perforin dependence of natural killer cell-mediated tumor control in vivo.

Authors:  M F van den Broek; D Kägi; R M Zinkernagel; H Hengartner
Journal:  Eur J Immunol       Date:  1995-12       Impact factor: 5.532

10.  Comparison of immune derangements in patients with different malignancies.

Authors:  A Lichtenstein; J Zighelboim; F Dorey; S Brossman; J L Fahey
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

View more
  7 in total

1.  Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.

Authors:  Dai-Wei Liu; Yuh-Cheng Yang; Ho-Fan Lin; Mei-Fang Lin; Ya-Wen Cheng; Chen-Chung Chu; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 2.  T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.

Authors:  A E Albers; L Strauss; T Liao; T K Hoffmann; A M Kaufmann
Journal:  Clin Dev Immunol       Date:  2010-12-27

Review 3.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

4.  Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.

Authors:  Andreas E Albers; Xu Qian; Andreas M Kaufmann; Daphne Mytilineos; Robert L Ferris; Thomas K Hoffmann; Albert B DeLeo
Journal:  Sci Rep       Date:  2018-07-16       Impact factor: 4.379

5.  MED15, transforming growth factor beta 1 (TGF-β1), FcγRIII (CD16), and HNK-1 (CD57) are prognostic biomarkers of oral squamous cell carcinoma.

Authors:  Maryam Elahi; Vahid Rakhshan
Journal:  Sci Rep       Date:  2020-05-21       Impact factor: 4.379

Review 6.  Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines.

Authors:  Qingyong Ng; Fang He; Jimmy Kwang
Journal:  Viruses       Date:  2015-12-08       Impact factor: 5.048

7.  Evaluation of natural killer cell (CD57) as a prognostic marker in oral squamous cell carcinoma: An immunohistochemistry study.

Authors:  Rashmi Agarwal; Minal Chaudhary; Shruti Bohra; Shree Bajaj
Journal:  J Oral Maxillofac Pathol       Date:  2016 May-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.